Morningstar1h
Merck in Cancer Licensing Pact With LaNova Medicines
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...
Merck Signs up to $3.3 Billion Cancer Drug Deal With China-Based LaNova
(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...
Joplin Globe3h
Merck to Participate in the Jefferies London Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Joseph Romanelli, president, Human Health International, and Dr. Marjorie Green, senior vice president and ...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...